About New Day Diagnostics

New Day Diagnostics was formed in 2014 with a mission of improving early detection of cancer. Our flagship products, Ovation and Procare, are being developed to provide reliable diagnostic tests for ovarian and prostate cancer. Beyond improving test performance, we strive to create tests that are simple and accessible to promote more regular testing of devastating diseases. As such, we’ve based our tests on novel biomarkers present in urine, which will offer efficient, noninvasive, and affordable detection methods to people all around the world. We hope that our diagnostics will have significant impact by enabling earlier intervention and improved survival.

Who We Are

Navroze Mehta

Founder - ceo

Navroze Mehta, Founder and CEO of New Day Diagnostics, has 15 years of experience in developing early stage medical devices. Most recently he was Managing Partner of MDI Partners LLC where he used a unique innovation and development framework to bring devices to market. One of those spin outs is ClearSpec LLC. Prior to MDI Partners, he was the Founder and CEO of NovaVision Inc., a venture-backed company that invented a neurostimulation devices to restore vision in stroke and traumatic brain injury patients. Before that he was President and CEO of Skinstore a successful B2C company. Navroze is a member of Young Presidents Organization (YPO), past chair of the Americas Gateway Chapter, and served as Regional Chair of the Economic Development Network. He was also a member of the Ashoka Support Network, a leader in the field of social entrepreneurship. Navroze also co-founded Mela Artisans Inc. with his daughter Sonali Mehta Rao. Mela Artisans is a novel social for profit enterprise that was formed to create a global marketplace for artisans worldwide with a goal of preserving the livelihood of artisans. Navroze also served on the Board of Directors of Mission Markets Inc., a company that is focused on connecting impact investors to mission-focused organizations. Navroze received an MBA from Syracuse University and a Bachelor of Commerce degree from Sydenham College at the University of Bombay, India.

John P. Keady


John Keady is President of New Day Diagnostics and Impact Medical Strategies. Serving in this capacity as a Sales, Marketing, and Commercial Operations executive, John brings extensive experience in channel management as well as bringing medical devices to market in multiple manufacturer and distributor leadership positions, both domestically and internationally. Prior to Impact Medical Strategies, John served in a variety of leadership roles at Welch Allyn including Sales, Channel Management, Customer Care, ERP Implementation, Quality and Regulatory, and General Management for businesses in the United States, Europe and Asia Pacific. Most recently he served on the Executive Committee and as Vice President, Sales and Marketing at AliMed developing and executing go-to-market strategies for print, digital, field and inside sales covering Acute Care, Post-Acute Care, Ambulatory Care, Extended Care and Consumer markets in both direct and indirect channels. John received a B.A. from the State University of New York at Geneseo where he was also inducted into the University’s Athletics Hall of Fame for Men’s Ice Hockey. His education also includes the University of Rochester William E. Simon Graduate School of Business, Rochester, NY (Senior Management) and the Macquarie Graduate School of Management, Sydney, Australia (General Management). He is a past member of the Healthcare Industry Distributors Association (www.hida.org) Acute Care Advisory Council, an organization focused on improving and advancing the value of distribution in healthcare.

Prem Gurnani

Prem Gurnani

CSO - VP Diagnostics

Prem Gurnani, Vice President of Diagnostics at New Day Diagnostics, is a scientific executive with 14+ years of driving strategic business development, clinical lab operations, and product development that effectively delivers innovation to the market. Prem is a strategic partner building collaborative relationships that connect resources within scientific, clinical, and pharmaceutical communities with SABs, KOLs, HCPs, and KDMs. He possesses strong working knowledge of clinical lab, reimbursement, regulatory, and compliance guidelines (CLIA, CAP, NY/CA State, FDA, OIG) and a strong understanding of market drivers in the personalized medicine market space. Prem is regarded for his ability to drive processes and motivate diverse teams while promoting organizational thought leadership through presentations and publications.